Pliant Therapeutics logo

Pliant Therapeutics

South San Francisco, CA

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

pliantrx.com

Company Details

Founded

2016

Employees

171 employees

Raised

$694,945,152

Headquarters Location

South San Francisco, CA

Public

Yes

Acquired

No

CEO

Bernard CoulieBernard Coulie

Founders

Hal Chapman
Hal Chapman
Bradley Backes
Bradley Backes
Bill DeGrado
Bill DeGrado
Dean Sheppard
Dean Sheppard

Company Collections

These are collections Pliant Therapeutics is a part of. Click on the collection name to view similar companies.

Pliant Therapeutics' Investors

Pliant Therapeutics' Tech Stack

Pliant Therapeutics Headquarters Location

260 Littlefield Ave, South San Francisco, CA 94080

Total Amount Raised: $694,945,152

Pliant Therapeutics' Investors

Pliant Therapeutics Funding Rounds

  • Post Ipo Equity

    $287,500,000

  • Post Ipo Equity

    $200,000,000

  • Series C

    $100,445,146

    Series C Investors

    Novartis
    Farallon Capital Management
    Redmile Group
    Surveyor Capital
    Menlo Ventures
    COWEN
    S-Cubed Capital
    Schroder Adveq
    Eventide
    Logos Capital
    Cormorant Asset Management
    Agent Capital
  • IPO

    Unknown

  • Series B

    $62,000,000

    Series B Investors

    COWEN
    Eventide
    Schroder Adveq
    Agent Capital
    Menlo Ventures
    S-Cubed Capital
  • Series A

    $45,000,000

    Series A Investors

    Third Rock Ventures
    pH Pharma
Funding info provided by Diffbot.

Pliant Therapeutics Reviews

0 out of 5 stars

Based on 0 reviews

Review data

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Pliant Therapeutics.

Recent reviews